Summit Therapeutics
SMMT

$12.27

2.4%

Market Cap: $8.89B

About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Employees: 105

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,686 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

170% more capital invested

Capital invested by funds: $208M [Q1] → $563M (+$355M) [Q2]

74% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 23

53% more call options, than puts

Call options by funds: $13.8M | Put options by funds: $9.02M

16% more funds holding

Funds holding: 104 [Q1] → 121 (+17) [Q2]

3.12% more ownership

Funds ownership: 7.17% [Q1] → 10.28% (+3.12%) [Q2]

57% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 47

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

30%

upside

Avg. target

$16

30%

upside

High target

$16

30%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target	30%upside $16	Buy Reiterated	3 Sept 2024
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target	30%upside $16	Buy Reiterated	21 Aug 2024
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target	30%upside $16	Buy Reiterated	15 Aug 2024
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target	30%upside $16	Buy Reiterated	14 Aug 2024
HC Wainwright & Co. Mitchell Kapoor 49% 1-year accuracy 58 / 119 met price target	30%upside $16	Buy Initiated	12 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about SMMT published over the past 30 days

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 102,000 shares of common stock. Awards were made to five new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committ.

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the primary analysis of the Phase III HARMONi-2 trial featuring its novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the Presidential Symposium at the International Association for the Study of Lung Cancer's (IASLC) 2024 World Conference on Lung Cancer (WCLC 2024) in San Diego, California. The presentation will take.

HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a Randomized Phase III Clinical Trial in NSCLC HONG KONG , Aug. 11, 2024 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) ("Akeso,") today announced two upcoming oral presentations of ivonescimab (PD-1/VEGF bispecific antibody) at the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer ("WCLC24"), taking place in San Diego, USA from September 7-10, 2024. Among these is a late-breaking Presidential Symposium presentation featuring results from the HARMONi-2/AK112-303 study, which evaluated monotherapy ivonescimab against monotherapy pembrolizumab in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression (PD-L1 TPS ≥1%).

Two Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024

Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript

Summit Therapeutics Inc. (NASDAQ:SMMT ) Q2 2024 Results Conference Call August 6, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and Chief Executive Officer Maky Zanganeh - Chief Executive Officer, President Manmeet Soni - Chief Operating Officer Allen Yang - Chief Medical Officer Conference Call Participants Dara Azar - Stifel Yigal Nochomovitz - Citigroup Mitchell Kapoor - H.C. Wainwright Operator Good morning, and welcome to Summit Therapeutics Second Quarter 2024 Earnings and Update Call.

Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 453,250 shares of common stock. Awards were made to fourteen new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Com.

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24/7 Wall Street

3 Small-Cap Stocks That Could Outperform the “Magnificent 7”

Recent headlines have highlighted the shift many investors are making from large-cap to small cap stocks.

3 Small-Cap Stocks That Could Outperform the “Magnificent 7”

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

SALT LAKE CITY--(BUSINESS WIRE)--As regulatory deadlines approach, 25 snack food suppliers align with ReposiTrak for its state-of-the-art, hardware-free traceability solutions.

25 Snack Food Suppliers Queue Up for ReposiTrak's Rapidly Expanding Food Traceability Network

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for the second quarter and six months ended June 30, 2024. Operational & Corporate Updates Our operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis.

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2024

Summit Therapeutics May Have Further Upside From Here

Summit Therapeutics to release second-quarter earnings and operational update on 6 August. Analysts are bullish on Phase 3 trial results for Ivonescimab in September, with a potential de-risking of the drug's profile. The company boosted its balance sheet with a $200 million institutional capital raise and expanded licensing territories after positive Phase I and II trial results.

Summit Therapeutics May Have Further Upside From Here

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its second quarter 2024 financial results and provide an operational update for the Company on Tuesday, August 6, 2024, before the market opens. Summit will host a live webcast of the earnings conference call at 9:00am ET, which will be accessible through our website www.smmttx.com. An archived edition of the session will be available on our website. About Iv.

Summit Therapeutics to Host Second Quarter 2024 Financial Results & Operational Progress Call on August 6, 2024

See News Rankings